 BofA analyst Cesar Tiron upgraded VEON Ltd NASDAQ: VEON to Buy from Underperform with a price target of 2.70, up from 1.60, implying a 46.7 upside. Stronger conviction regarding the companys operational recovery following 5.5 billion of cumulative Capex in 2019-2021 led to the re-rating. 